Skip to main content

Table 5 CTGF/log10 (VEGF) ratios

From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage

Variables Value P value
Group B
Ratio CTGF/log10(VEGF) before IVR 0.399 ± 0.141 0.051
Ratio CTGF/log10(VEGF) after IVR 0.724 ± 0.624  
Group C
Ratio CTGF/log10(VEGF) before IVR 0.553 ± 0.284 0.046
Ratio CTGF/log10(VEGF) after IVR 0.803 ± 0.387